These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 24389322

  • 1. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L.
    Orv Hetil; 2014 Jan 12; 155(2):62-8. PubMed ID: 24389322
    [Abstract] [Full Text] [Related]

  • 2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 12; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 3. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 12; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

  • 4. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 5. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
    Grundy SM.
    Nat Rev Cardiol; 2016 Feb 01; 13(2):74-5. PubMed ID: 26763537
    [No Abstract] [Full Text] [Related]

  • 6. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM, Shah S, Kher U, Hunter JA, Gill GG, Cressman MD, Ashraf TB, Johnson-Levonas AO, Mitchel YB.
    Am J Cardiol; 2017 Feb 01; 119(3):388-396. PubMed ID: 27956003
    [Abstract] [Full Text] [Related]

  • 7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 8. Ongoing challenges for pharmacotherapy for dyslipidemia.
    Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ.
    Expert Opin Pharmacother; 2015 Feb 13; 16(3):347-56. PubMed ID: 25476544
    [Abstract] [Full Text] [Related]

  • 9. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 08; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Oct 08; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 12. [Antibodies in addition to statin therapy lowers LDL cholesterol].
    Bossenmayer S.
    Dtsch Med Wochenschr; 2012 Sep 08; 137(36):1728. PubMed ID: 23281534
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I.
    Arq Bras Endocrinol Metabol; 2006 Apr 08; 50(2):344-59. PubMed ID: 16767301
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy in dyslipidemia: where are we now?
    Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM.
    Atherosclerosis; 2014 Nov 08; 237(1):319-35. PubMed ID: 25299967
    [Abstract] [Full Text] [Related]

  • 15. [Multimodal therapy of dyslipidemia].
    Stahn A, Hanefeld M.
    Clin Res Cardiol Suppl; 2011 May 08; 6():10-6. PubMed ID: 22528173
    [Abstract] [Full Text] [Related]

  • 16. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M.
    N Engl J Med; 2009 Nov 26; 361(22):2113-22. PubMed ID: 19915217
    [Abstract] [Full Text] [Related]

  • 17. Use of combination therapy for dyslipidemia: a lipid clinic approach.
    Brown AS.
    Am J Cardiol; 2002 Nov 20; 90(10B):44K-49K. PubMed ID: 12467939
    [Abstract] [Full Text] [Related]

  • 18. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R.
    Lancet; 2012 Jul 07; 380(9836):29-36. PubMed ID: 22633824
    [Abstract] [Full Text] [Related]

  • 19. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A, Katsiki N, Karagiannis A, Athyros V.
    Curr Vasc Pharmacol; 2020 Jul 07; 18(1):38-42. PubMed ID: 30663570
    [Abstract] [Full Text] [Related]

  • 20. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
    Lee P, Hegele RA.
    Expert Opin Investig Drugs; 2013 Nov 07; 22(11):1411-23. PubMed ID: 23889692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.